1. Introduction {#s0005}
===============

Acute kidney injury (AKI) is a severe condition with high morbidity and mortality. AKI is associated with a \> 2.2--4 times increased likelihood of death in hospitalized patients ([@bb0140], [@bb0120]). Contrast-induced nephropathy (CIN) is the third leading cause of hospital acquired AKI due to iodinated contrast media used in diagnostic and interventional procedures ([@bb0055], [@bb0015]). Despite prevention strategies are improved, the increasing incidence of CIN is still challenging. Novel prophylactic and treatment strategies to decrease CIN are urgently needed.

Up to now, the exact underlying mechanism of CIN remains unclear. It has been generally suggested that renal hypoperfusion, direct toxic tubular injury, inflammatory response and oxidative stress are involved in the pathogenesis of CIN ([@bb0090], [@bb0150], [@bb0115]).

Among numerous candidates that possess reno-protective effects, Antithrombin III (ATIII) is not only a powerful anticoagulant but also possesses anti-inflammatory properties ([@bb0010], [@bb0035]). It has been reported that administration of exogenous ATIII could protect against organ ischemia/reperfusion injury (IRI) ([@bb0070], [@bb0025]). Importantly, our recent study showed that patients with low ATIII activity were more vulnerable to AKI after cardiac surgery and endogenous ATIII insufficiency exacerbated renal injury in an animal model ([@bb0110]). However, the role of ATIII in contrast induced AKI has not been previously investigated.

In the current study, we examined whether low plasma ATIII activity increased the risk of CIN and whether exogenous ATIII administration had reno-protective effects in CIN. In addition, the underlying mechanism of ATIII\'s protective effects against contrast induced AKI was investigated.

2. Materials and Methods {#s0010}
========================

2.1. ATIII Activities and the Incidence of AKI in Patients Undergoing CAG {#s0015}
-------------------------------------------------------------------------

This study was approved by the ethics committee of Shanghai Jiao Tong University Affiliated Sixth People\'s Hospital. Patients undergoing CAG in our hospital were eligible for inclusion while patients with endocarditis, hepatic diseases, and baseline Scr levels \> 106 μmol/l were excluded. For the diagnosis of AKI, we adopted KDOQI 2012 criteria for acute kidney injury ([@bb0075]). Plasma ATIII activities were measured before CAG. ATIII activities were measured using an automatic coagulation analysis machine (Sysmex CA7000, SIEMENS, Munich, Germany). Low or normal ATIII activity was defined as previously described ([@bb0110]).

2.2. Animals and Reagents {#s0020}
-------------------------

Male Sprague-Dawley rats, weighing 250 ± 20 g, were purchased from Shanghai Science Academy animal center. This study was approved by the Animal Care and Ethics Committee of Shanghai Jiao Tong University Affiliated Sixth People\'s Hospital. All the procedures were conducted in accordance with the policies for the Care and Use of Laboratory Animals of our institution.

Loversol was purchased from Hengrui Corp. (Jiansu, China). *N*-nitro-*L*-arginine methyl ester (L-NAME), indomethacin, sodium taurocholate and ATIII recombinant protein were from Sigma-Aldrich (St Louis, Mo, USA).

2.3. Animal Study Protocols {#s0025}
---------------------------

Study was designed to determine whether exogenous ATIII administration could protect against contrast induced AKI. CIN model was established as described previously ([@bb0145]). Briefly, rats were given a tail vein injection of indomethacin (10 mg/kg), followed by Ioversol (3 g/kg organically bound iodine) and L-NAME. 48 rats were randomly divided into four groups (n = 6 in each group): sham-operated group with injection of normal saline (sham + vehicle), CIN group with injection of normal saline (CIN + vehicle), CIN group with pre-injection of ATIII (CIN + pre-ATIII), CIN group with post-injection of ATIII (CIN + post-ATIII). ATIII (500 μg/kg) or an equivalent volume of vehicle was intravenously delivered 30 min before or after CIN. The ATIII dose used to reduce kidney injury was chosen based on a previous study ([@bb0020]). The animals were killed 24 h or 36 h after induction of CIN. Blood and renal tissues were harvested for analysis.

2.4. Kidney Sonography Examinations {#s0030}
-----------------------------------

Kidney sonography was performed using an Esote Mylab Twice device (Esaote, XVISION, Italy) with 2.5 MHz transducer as previously described ([@bb0100]). Doppler ultrasound examinations and calculation of intrarenal resistance index (RI) were performed on the left kidney. RI values were calculated automatically by the device using a standard formula (RI = \[peak systolic velocity-peak diastolic velocity/peak systolic velocity). RI assessments were made 24 h after CIN.

2.5. Measurement of Biochemistry Parameters and Oxidative Stress Markers {#s0035}
------------------------------------------------------------------------

Scr and BUN were measured by an automatic biochemical analyzer 7600 (Hitachi, Tokyo, Japan) to assess the alteration of renal function. The levels of MDA and SOD in renal tissue homogenate were measured using commercial kits following the manufacturer\'s protocol (Nanjing Jiancheng, Nanjing, Jiangsu, China).

2.6. Histological Injury Assessment and Immunohistochemical Staining {#s0040}
--------------------------------------------------------------------

The paraformaldehyde-fixed kidney was embedded in paraffin and then was cut into 3 μm sections. Histological alterations were evaluated by Periodic acid--Schiff (PAS) staining. The renal injury was evaluated using a scoring system grading tubular necrosis, tubular dilatation, loss of brush border, and cast formation in 10 randomly chosen, non-overlapping fields. The severity of renal injury was semiquantified by the following criteria: 0, none; 1, 0--10%; 2, 11--25%; 3, 26--45%; 4, 46--75%; and 5, 76--100%, as described previously ([@bb0050]).

Kidney sections were stained with an anti-F4/80 antibody (Abcam, Cambridge, MA, USA) to detect macrophage infiltration in renal tissue as described previously ([@bb0130], [@bb0135]).

2.7. Quantitative Real-Time PCR {#s0045}
-------------------------------

Total RNA from HK2 cells or kidney tissues was isolated using Trizol (Invitrogen, Carlsbad, CA, USA) and was reverse transcribed into cDNA with M-MLV Reverse Transcriptase (Promega, Madison, WI, USA). Real-time PCR was performed with Power SYBR® Green PCR Master Mix (Applied Biosystems, Foster City, CA, USA) as described previously. ([@bb0105]) The specific primers were as following: rat TNFα: 5′GTCTGTGCCTCAGCCTCTTC3′ (forward) and 5′TGGAACTGATGAGAGGGAGC3′ (reverse); rat MCP-1: 5′CCCCACTCACCTGCTGCTAC3′ (forward) and 5′CCTGCTGCTGGTGATTCTCTT3' (reverse); rat ICAM-1:5′GAGACCCCGTTGCCTAAA3′ (forward) and 5′CCGCAGGTCCAGTTCAGT-3' (reverse); human MCP-1: 5′TGCAGAGGCTCGCGAGCTA3' (forward) and 5′CAGGTGGTCCATGGAATCCTGA3' (reverse); human ICAM-1: 5′GGCCTCAGTCAGTGTGA3' (forward) and 5′AACCCCATTCAGCGTCA3' (reverse); Quantitation was normalized to internal control 18S rRNA and 2^− ΔΔCT^ method was used to determine relative gene expression level.

2.8. Western Blot Analysis {#s0050}
--------------------------

The primary antibodies, rabbit anti-caspase-3, anti-bcl-2 and mouse anti-Tubulin were both from Cell Signaling Technology (Danvers, MA, USA). Horseradish peroxidase--conjugated secondary antibodies (Beyotime, Suzhou, Jiangsu, China) were used and bands were visualized by Image Quant LAS 4000 Mini System (GE Healthcare, Pittsburgh, PA, USA).

2.9. Statistical Analysis {#s0055}
-------------------------

The statistical software SPSS (Ver. 19.0) (IBM, Armonk, NY, USA) was used for data analysis. All the data were expressed as mean ± standard deviation. One-way ANOVA with Sidak compensation was employed for parametric data comparison. Statistical significance was defined as *P* \< 0.05.

3. Results {#s0060}
==========

3.1. Patients With Low ATIII Activity Presented a Higher Risk for Developing AKI After Coronary Angiography {#s0065}
-----------------------------------------------------------------------------------------------------------

We assessed whether low plasma ATIII activity increased the risk of AKI following coronary angiography. All 209 eligible patients undergoing CAG in our hospital from July 1, 2014 to Dec 31, 2015 were examined. Of these 209 cases, 31 had low ATIII activity before CAG procedure, among which, 12 (or 38.7%) developed AKI after CAG. Of the 178 cases with normal ATIII activity, 10 (or 5.6%) developed AKI after CAG. The incidence of AKI was significantly higher in patients with low ATIII activity (Fisher\'s exact test, *P* \< 0.05, [Table 1](#t0005){ref-type="table"}).

There was no significant difference in diabetes incidence, proteinuria, baseline serum creatinine (Scr), peak Scr, hemoglobin, D-dimer, alanine aminotransferase, and heart failure between the two groups ([Table 1](#t0005){ref-type="table"}). There was no nephrotoxic drug use except necessary anticoagulatory agents and diuretics. Moreover, we divided these patients into quartiles based on ATIII activities and observed that the lowest quartile presented a significantly higher incidence of subsequent AKI ([Table 2](#t0010){ref-type="table"}), consistent with the analysis based on clinically defined low and normal ATIII activities. Thus, Patients with low ATIII activity presented a higher risk for developing AKI after CAG.

3.2. Antithrombin III Attenuated Contrast Induced Renal Dysfunction and Renal Histological Injury {#s0070}
-------------------------------------------------------------------------------------------------

We used an experimental model to confirm whether exogenous ATIII administration had beneficial effects on CIN and underlying mechanisms. ATIII (500 μg/kg) or an equivalent volume of vehicle was intravenously infused 30 min before or after CIN. Administration of ATIII significantly attenuated the elevation of serum creatinine, blood urea nitrogen (BUN) in the CIN model at 24 h ([Fig. 1](#f0005){ref-type="fig"}). Moreover, the reno-protective effects of ATIII were sustained to 36 after contrast infusion in ATIII pre-administered rats whereas post-administration of ATIII could not decrease the elevation of Scr and BUN in CIN rats at 36 h.

Consistent with the Scr and BUN data, histological analysis demonstrated that the renal tubular detachment, brush border loss, and necrosis of tubular cells were improved in ATIII pre-administered CIN groups compared with CIN + vehicle group ([Fig. 1](#f0005){ref-type="fig"}d and e). Therefore, exogenous ATIII administration could attenuate contrast induced renal dysfunction and renal histological injury.

3.3. Antithrombin III Attenuated Renal Inflammation and Oxidative Stress in CIN Rats {#s0075}
------------------------------------------------------------------------------------

To explore the reno-protective mechanisms of ATIII in CIN, the effects of ATIII on inflammation and oxidative stress were examined. As shown in [Fig. 2](#f0010){ref-type="fig"}a, CIN rats showed substantially increased the mRNA expression level of renal tumor necrosis factor α (TNFα) concentration, while both pre- and post-administration of ATIII significantly decreased renal TNFα expression. The mRNA expression levels of renal monocyte chemotactic protein 1 (MCP-1) and intercellular cell adhesion molecule 1 (ICAM-1) in CIN rats were significantly increased compared with sham rats, and pre-administration but not post-administration of ATIII inhibited MCP-1 and ICAM-1 expression in CIN rats ([Fig. 2](#f0010){ref-type="fig"}b and c). Immunostaining analysis showed that CIN led to increased intrarenal F4/80-positive cells infiltration, which was mitigated by post- or pre-administration of ATIII ([Fig. 2](#f0010){ref-type="fig"}d and e).

Furthermore, ATIII administration decreased renal oxidative stress levels in CIN rats ([Fig. 3](#f0015){ref-type="fig"}). Renal malondialdehyde (MDA) levels were increased in CIN rats, which were attenuated by pre- or post- administration of ATIII ([Fig. 3](#f0015){ref-type="fig"}a). Renal superoxide dismutase (SOD) activity was decreased in CIN rats, which was significantly attenuated by pre-administration of ATIII, but not post-administration ([Fig. 3](#f0015){ref-type="fig"}b). In addition, ATIII treatment effectively restored renal cortical blood supply and reduced intrarenal resistance index in CIN rats ([Fig. 4](#f0020){ref-type="fig"}). These data indicated that ATIII might elicit its beneficial effects by inhibiting inflammatory response, oxidative stress and improving renal blood flow.

3.4. Effects of Antithrombin III on Renal Cell Apoptosis in CIN Rats {#s0080}
--------------------------------------------------------------------

To determine whether ATIII was involved in cell apoptosis, expression of caspase-3 and bcl-2 was analyzed. As shown in [Fig. 5](#f0025){ref-type="fig"}, CIN led to substantial increase in cleaved caspases-3 expression, which was attenuated by pre- or post- administration of ATIII (*P* \< 0.05). The expression of anti-apoptosis bcl-2 was significantly increased in ATIII pre-treated CIN group compared with un-treated CIN rats (*P* \< 0.05). In summary, ATIII administration mitigated renal cell apoptosis following CIN.

4. Discussion {#s0085}
=============

This study demonstrated an important role of ATIII in the endogenous defense mechanisms against medium contrast induced AKI and provided molecular mechanisms of ATIII\'s reno-protective properties. We found that lower plasma ATIII activity was associated with higher incidence of AKI following CAG. Furthermore, the prophylactic and therapeutic administration of ATIII could effectively improve renal functional and structural damage in contrast induced AKI. The reno-protective effects of ATIII might be mediated by inhibition of inflammation, oxidative stress, apoptosis and improving renal blood flow.

The clinical study results indicate that plasma ATIII could be a useful predictor of AKI in patients received coronary angiography and more proactive prophylactic measures should be taken to prevent the occurrence of AKI in patients with low ATIII activity.

ATIII is not only an inhibitor of thrombin and other serine proteases of the clotting cascade, but also possesses anti-inflammatory and cyto-protective effects ([@bb0085], [@bb0040], [@bb0045]). In accordance with our recent studies ([@bb0110]) and other studies ([@bb0070]), ATIII supplementation appears to attenuate contrast induced renal dysfunction through inhibiting inflammation, oxidative stress, and apoptosis.

It has been recognized that hypoxia, endotoxins, and multiple drugs can directly activate renal resident leukocytes and prime intrarenal inflammation ([@bb0080]). Compared with untreated CIN rats, ATIII administration alleviated intrarenal inflammation and F4/80-positive cells infiltration. ATIII-treated CIN rats exhibited less expression of renal TNFα, MCP-1, and ICAM-1. It appears that ATIII is a crucial anti-inflammatory mediator against local renal inflammation. Nevertheless, how ATIII exerts its anti-inflammatory effects remains elusive. It has been reported that the mechanisms underlying anti-inflammatory properties of ATIII include inhibiting neutrophils recruitment and leukocytes rolling and infiltration ([@bb0065], [@bb0125]), pro-inflammatory cytokines secretion ([@bb0095]) and protection in vascular endothelium ([@bb0060]). Besides, ATIII can directly inhibit nuclear factor (NF)-κB pathways and leucocytes activation ([@bb0155], [@bb0060]). Thus, ATIII might elicit its beneficial effects on contrast induced AKI by inhibiting inflammatory response.

Excess production of oxygen radical and cell apoptosis is involved in the pathogenesis of CIN. Our data showed that ATIII had inhibitory effects on renal oxidative stress in AKI following contrast infusion. Moreover, tubular cell apoptosis was mitigated in ATIII-administered rats.

Continued renal hypoperfusion plays a pivotal role in the development of CIN ([@bb0030]). Due to their high energy demand and complicated microvascular network, kidneys are especially vulnerable to ischemic injury. Contrast media infusion can directly decrease renal blood flow leading to subsequent renal I/R injury. Our results showed that ATIII administration significantly restored renal blood flow in ATIII--treated CIN rats compared with untreated CIN rats. This hemodynamic alteration may be attributed to increased levels of prostaglandin I~2~ (PGI~2~), which is a powerful vasodilator. Our previous study also found blunted compensatory elevation of PGI~2~ due to ATIII insufficiency might be responsible for renal IRI ([@bb0110]). These results indicate that ATIII might indirectly increase renal blood flow via upregulating PGI~2~.

Clinical studies have demonstrated that the ATIII activity is considerably decreased in critically ill patient with sepsis and pancreatitis ([@bb0005]). Our study also found that ATIII activity was decreased in experimental model of CIN. ATIII deficiency might be caused by increased ATIII consumption and impaired synthesis. In this study, administration of ATIII did not increase the activity of ATIII. This phenomenon could be explained as follows: First, the dose of ATIII was too minimal to influence the anticoagulation activity of ATIII and low dose of ATIII might exert its beneficial effects via its anti-inflammation properties; Second, ATIII might have been metabolized by 24 h after surgery due its consumption.

The present also had some limitations. First, clinical data indicated that insufficiency of endogenous ATIII increased the risk of AKI after coronary angiography. Although confounding factors were partially adjusted by using control group, there still exists a limitation due to the failure to control all factors simultaneously in observational studies. By the way, the animal study only investigated the effect of exogenous ATIII on CIN rats; further study should focus on the role of the endogenous ATIII in the development of CIN. Besides, we used F4/80-positive cells to represent macrophage, however, F4/80-positive cell also includes monocyte. Because there is still no more specific antibody for macrophage so far, it would be more accurate to examine the macrophage infiltration by using double or triple-staining flow cytometry in isolated renal immune cells.

The findings of this study provided novel insights into the mechanisms of ATIII\'s protection against CIN. ATIII deficiency due to chronic diseases or genetic variations may predispose patients to AKI. Whether prophylactic and therapeutic administration of ATIII can effectively prevent CIN incidence and promote survival in patients also warrants further investigation. This study will give us some new views on antithrombin function and prevention of kidney injury ([@bb0040], [@bb0045], [@bb0130], [@bb0135]).
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![Antithrombin III attenuated renal injury in contrast induced nephropathy (CIN). Contrast induced nephropathy model was induced by intravenous injection of Ioversol and L-NAME in Sprague-Dawley rats. Blood and kidney tissues were collected 24 h or 36 h after CIN, respectively. (a) Plasma AT III activity at 24 h after CIN. (b) Blood urea nitrogen. (c) Serum creatinine. (d) Renal histological alterations by Periodic acid--Schiff (PAS) staining (representative pictures, 400 ×, PAS) at 24 h. (e) Quantitative analysis of tubular injury scoring at 24 h. Sham + vehicle, sham-operated group with normal saline injection; CIN + vehicle, contrast induced nephropathy group with normal saline injection; CIN + pre-ATIII, contrast induced nephropathy group following ATIII injection; CIN + post-ATIII, contrast induced nephropathy group with ATIII post-injection. N = 6, ^⁎^*P* \< 0.05, ^⁎⁎⁎^*P* \< 0.001 versus Sham + vehicle at 24 h; ^\#^*P* \< 0.05, ^\#\#\#^*P* \< 0.001 versus CIN + vehicle at 24 h. ^\^\^\^^*P* \< 0.001 versus Sham + vehicle at 36 h; ^△^*P* \< 0.05 versus CIN + vehicle at 36 h.](gr1){#f0005}

![Antithrombin III treatment mitigated renal inflammation in CIN rats. Kidney tissues were collected at 24 h after CIN. (a) Renal TNFα mRNA expression. (b) Renal MCP-1 mRNA expression. (c) Renal ICAM-1 mRNA expression. (d) Representative images of immunostaining of F4/80 (400 ×). (e) Quantitative analysis of F4/80 positive cells. N = 6, ^⁎^*P* \< 0.05, ^⁎⁎^*P* \< 0.01, ^⁎⁎⁎^*P* \< 0.001 versus Sham + vehicle; ^\#^*P* \< 0.05, ^\#\#^*P* \< 0.01 versus CIN + vehicle.](gr2){#f0010}

![Antithrombin III treatment decreased renal oxidative stress in CIN rats. Kidney tissues were collected 24 h after CIN. (a) Renal MDA. (b) Renal SOD. N = 6, ^⁎^*P* \< 0.05, ^⁎⁎⁎^*P* \< 0.001 versus Sham + vehicle; ^\#^*P* \< 0.05, ^\#\#^*P* \< 0.01 versus CIN + vehicle.](gr3){#f0015}

![Antithrombin III administration improved renal blood flow in CIN rats. Ultrasonography was performed at 24 h after contrast infusion. (a) Representative pictures of distribution of renal blood flow. (b) Quantitative analysis of intrarenal resistance index (RI). N = 6, ^⁎⁎^*P* \< 0.01 versus Sham + vehicle; ^\#^*P* \< 0.05 versus CIN + vehicle.](gr4){#f0020}

![Renal cells apoptosis was diminished after antithrombin III administration in CIN rats. Tissues were collected 24 h after CIN. (a) Caspase-3 protein abundance in renal cortex. (b) Bcl-2 protein abundance in renal cortex. N = 6, ^⁎⁎^*P* \< 0.01 versus Sham + vehicle; ^\#^*P* \< 0.05 versus CIN + vehicle.](gr5){#f0025}

###### 

Incidences of AKI following CAG in patients with low or normal ATIII activities.

Table 1

                                      Normal ATIII (n = 178)   Low ATIII (n = 31)   *P*
  ----------------------------------- ------------------------ -------------------- ---------
  Gender (male/female)                94/84                    17/14                \> 0.05
  Age (years)                         69.3 ± 13.1              68.8 ± 17.6          \> 0.05
  ATIII activity, % (median, range)   95.6, 78.4--115          69.8 (52.1--74.8)    \< 0.05
  AKI, %                              10, 5.6%                 12, 38.7%            \< 0.05
  Baseline Scr (μmol/l)               83.3 ± 22.7              78.2 ± 14.7          \> 0.05
  Peak Scr of AKI patients (μmol/l)   204.4 ± 33.1             217 ± 35.9           \> 0.05
  Proteinuria (n, %)                  12, 6.7%                 3, 9.7%              \> 0.05
  Diabetes (n, %)                     32, 18.0%                6, 19.3%             \> 0.05
  Hb (g/L)                            115.2 ± 13.1             123.6 ± 23.8         \> 0.05
  D-dimer (mg/L)                      2.0 ± 0.9                1.8 ± 1.0            \> 0.05
  ALT (U/L)                           69.1 ± 35.2              54.3 ± 19.6          \> 0.05
  Heart failure (n, %)                20, 11.2%                5, 16.1%             \> 0.05
  AMI (n, %)                          37, 20.8%                8, 25.8%             \> 0.05

Abbreviations: CAG, coronary angiography; AKI, acute kidney injury; ATIII, antithrombin III; Scr, serum creatinine; Hb, hemoglobin; ALT, alanine aminotransferase; Scr, serum creatinine; AMI: acute myocardial infraction.

###### 

AKI incidences in CAG patients divided into quartiles based on ATIII activities.

Table 2

  Group        N    ATIII activity   AKI incidence
  ------------ ---- ---------------- ----------------------------------------------
  Quartile 1   53   69.3--88%        17/53, 32%[\#](#tf0005){ref-type="table-fn"}
  Quartile 2   56   89--99%          2/56, 3.6%
  Quartile 3   48   101--107%        1/48, 2.1%
  Quartile 4   52   108--115%        2/52, 3.8%

Abbreviations: CAG, coronary angiography; AKI, acute kidney injury; ATIII, antithrombin III.

*P* \< 0.05, versus group quartiles 2, 3, and 4.
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